---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-167868"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:45:38.116227+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Teva shareholders reject advisory vote on executive compensation at 2023 annual meeting

## Summary
- Elected directors Sol J. Barer and Janet S. Vergis with ~490M and ~498M votes for, respectively.
- Say-on-pay proposal failed: 319.2M for, 324.5M against, showing majority disapproval.
- Auditor Kesselman & Kesselman (PwC) ratified with 712.7M votes for, 35.8M against.
- Approximately 103.9M broker non-votes on director and say-on-pay items.

## SEC filing metadata
- accession: 0001193125-23-167868
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312523167868/0001193125-23-167868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312523167868/d514530d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-167868
- JSON: https://secwatch.observer/filing/0001193125-23-167868.json
- Plain text: https://secwatch.observer/filing/0001193125-23-167868.txt

## Key facts
- Shareholder Votes
  TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Ratification of appointment of Kesselman & Kesselman (PwC) as independent auditor at the 2023-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders, as follows: For Against Abstain Brokers non-vote 712,745,286 35,777,701 1,019,646 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312523167868/0001193125-23-167868-index.htm
- Shareholder Votes
  TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders rejected Non-binding advisory vote on executive compensation at the 2023-06-15 meeting.
  - Proposal: say on pay
  - Outcome: failed
  - Meeting: 2023-06-15
  source text: The shareholders did not approve, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows: For Against Abstain Brokers non-vote 319,197,368 324,474,010 5,417,079 103,855,164
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312523167868/0001193125-23-167868-index.htm
- Shareholder Votes
  TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Election of Directors at the 2023-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2026 annual meeting of shareholders, as follows: Directors For Against Abstain Brokers non-vote Dr. Sol J. Barer 490,224,315 153,968,878 4,893,082 103,855,164 Janet S. Vergis 498,422,096 145,733,938 4,930,241 103,855,164
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312523167868/0001193125-23-167868-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.